Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Laboratory Corp of America (LH)  
$210.59 2.54 (1.19%) as of 4:30 Fri 5/17


Download
   
Exchange: New York Stock Exchange
Security Type: Common
Shares Out: 97,400,000
Market Cap: 20.51(B)
Last Volume: 730,917 Avg Vol: 762,335
52 Week Range: $197.69 - $241.33
Level I Sector: Health Care
Level II Sector: Health Services
Level III Sector: Medical Laboratories & Research

Member Indexes:
    S&P COMPOSITE 1500     NYSE COMPOSITE
    S&P 500

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  274
Guru Rank Value     : 4.4
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Laboratory Corporation of America Holdings is a life sciences company that provides information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make decisions. Co. reports its business in two segments, LabCorp Diagnostics (Dx) and Labcorp Drug Development (DD). Dx is an independent clinical laboratory business. It provides a menu of requested and specialty testing through a network of primary and specialty laboratories across the U.S. DD provides drug development, medical device and diagnostic development solutions from early-stage research to clinical development and commercial market access.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 44
Total Buy Value $0 $0 $0 $10,251
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 58,748 59,437 70,333 142,059
Total Sell Value $12,670,986 $12,824,739 $15,157,786 $32,185,253
Total People Sold 7 7 8 8
Total Sell Transactions 11 14 18 29
End Date 2024-02-18 2023-11-17 2023-05-19 2022-05-19

   
Records found: 933
  Page 14 of 38  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Belingard Jean Luc Director   •       •      –    2021-05-03 4 OE $98.49 $256,074 D/D 2,600 18,169     -
   Van Der Vaart Sandra D EVP, Chief Legal Officer   •       •      –    2021-03-30 4 AS $251.88 $204,527 D/D (812) 5,237 19%     
   Schroeder Mark S EVP, President-Diagnostics Lab   •       •      –    2021-03-30 4 AS $251.88 $168,004 D/D (667) 5,006 19%     
   Caveney Brian J EVP, President of Diagnostics   •       •      –    2021-03-27 4 D $251.58 $271,455 D/D (1,079) 8,001     -
   Caveney Brian J EVP, President of Diagnostics   •       •      –    2021-03-27 4 A $0.00 $0 D/D 2,413 9,080     -
   Berberian Lance EVP, CIO & CTO   •       •      –    2021-03-27 4 D $251.58 $271,455 D/D (1,079) 14,186     -
   Berberian Lance EVP, CIO & CTO   •       •      –    2021-03-27 4 A $0.00 $0 D/D 2,413 15,265     -
   Van Der Vaart Sandra D EVP, Chief Legal Officer   •       •      –    2021-03-27 4 D $251.58 $172,835 D/D (687) 6,049     -
   Van Der Vaart Sandra D EVP, Chief Legal Officer   •       •      –    2021-03-27 4 A $0.00 $0 D/D 2,310 6,736     -
   Schroeder Mark S EVP, President-Diagnostics Lab   •       •      –    2021-03-27 4 D $251.58 $271,455 D/D (1,079) 5,673     -
   Schroeder Mark S EVP, President-Diagnostics Lab   •       •      –    2021-03-27 4 A $0.00 $0 D/D 2,413 6,752     -
   Eisenberg Glenn A Chief Financial Officer, EVP   •       •      –    2021-03-27 4 D $251.58 $904,430 D/D (3,595) 37,433     -
   Eisenberg Glenn A Chief Financial Officer, EVP   •       •      –    2021-03-27 4 A $0.00 $0 D/D 8,042 41,028     -
   Kirchgraber Paul R CEO, Covance Drug Development   •       •      –    2021-03-27 4 D $251.58 $198,748 D/D (790) 9,786     -
   Kirchgraber Paul R CEO, Covance Drug Development   •       •      –    2021-03-27 4 A $0.00 $0 D/D 2,104 10,576     -
   Wilkinson Peter J SVP, Chief Accounting Officer   •       •      –    2021-02-18 4 OE $146.59 $340,251 D/D 2,166 976     -
   Wilkinson Peter J SVP, Chief Accounting Officer   •       •      –    2021-02-18 4 S $241.51 $559,589 D/D (2,317) 343 -14%     
   Schroeder Mark S EVP, President-Diagnostics Lab   •       •      –    2021-02-16 4 AS $237.06 $44,567 D/D (188) 4,339 13%     
   Van Der Vaart Sandra D EVP, Chief Legal Officer   •       •      –    2021-02-16 4 AS $235.89 $49,202 D/D (208) 4,426 13%     
   Wilkinson Peter J SVP, Chief Accounting Officer   •       •      –    2021-02-12 4 D $238.26 $62,662 D/D (263) 1,127     -
   Wilkinson Peter J SVP, Chief Accounting Officer   •       •      –    2021-02-12 4 OE $0.00 $0 D/D 867 1,328     -
   Berberian Lance EVP, CIO & CTO   •       •      –    2021-02-12 4 D $238.26 $208,001 D/D (873) 12,852     -
   Berberian Lance EVP, CIO & CTO   •       •      –    2021-02-12 4 OE $0.00 $0 D/D 2,940 12,957     -
   Schroeder Mark S EVP, President-Diagnostics Lab   •       •      –    2021-02-12 4 D $238.26 $33,833 D/D (142) 4,527     -
   Schroeder Mark S EVP, President-Diagnostics Lab   •       •      –    2021-02-12 4 OE $0.00 $0 D/D 517 4,605     -
  933 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 14 of 38
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us